122
Participants
Start Date
May 30, 2008
Primary Completion Date
April 18, 2019
Study Completion Date
April 1, 2020
Placebo
Subcutaneous injection, twice a day
Exenatide
Subcutaneous injection, 5 µg, twice a day
Exenatide
Subcutaneous injection,10 µg, twice a day
Research Site, Moloto South
Research Site, Quezon City
Research Site, Verulam
Research Site, Paarl
Research Site, Jamaica
Research Site, Aguascalientes
Research Site, Raleigh
Research Site, Greenville
Research Site, Dalton
Research Site, Tallahassee
Research Site, Pensacola
Research Site, Orlando
Research Site, Melbourne
Research Site, Miami Lakes
Research Site, Miami
Research Site, Birmingham
Research Site, Memphis
Research Site, Guadalajara
Research Site, Indianapolis
Research Site, Dearborn
Research Site, Chicago
Research Site, Chicago
Research Site, St Louis
Research Site, Kansas City
Research Site, Monterrey
Research Site, Wichita
Research Site, Dallas
Research Site, San Juan del Río
Research Site, San Antonio
Research Site, Aurora
Research Site, Culiacán
Research Site, Tucson
Research Site, Tamaupilas
Research Site, Tampico
Research Site, Reno
Research Site, Los Angeles
Research Site, Montclair
Research Site, San Diego
Research Site, Santa Ana
Research Site, Sacramento
Research Site, Spokane
Research Site, Moscow
Research Site, Ahmedabad
Research Site, Ufa
Research Site, Tomsk
Research Site, Oklahoma City
Research Site, Fortaleza
Research Site, Juiz de Fora
Research Site, Santo André
Research Site, Bangalore
Research Site, Pune
Research Site, Seoul
Research Site, Pretoria
Lead Sponsor
Quintiles, Inc.
INDUSTRY
AstraZeneca
INDUSTRY